{"id":"W3217494531","doi":"10.1016/s1470-2045(21)00578-7","title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Loxo Oncology; PharmaMar; Innovent Biologics; Incyte; Sanofi; Andrew Sabin Family Foundation; National Institutes of Health; Helsinn; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Glioma; Glioblastoma; Temozolomide; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001295313,0.00185466,0.002566667,0.0003463523,0.0002986518,0.001257937,0.0007702502,0.001158278,0.003601403],"category_scores_gemma":[0.001032637,0.0004798234,0.002073719,0.0004587843,0.0006629407,0.001395645,0.0003925028,0.003114601,0.0009196071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071808,"about_ca_system_score_gemma":0.0009922005,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001670793,"about_ca_topic_score_gemma":0.005610406,"domain_scores_codex":[0.9995984,0.000164996,0.00002124775,0.00008264325,0.00002747317,0.0001051903],"domain_scores_gemma":[0.9995791,0.00007239521,0.0001019541,0.00002986804,0.00003035639,0.0001862563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9235789,0.004451344,0.002576794,0.001320553,0.00281182,0.0001105528,0.0001294804,0.001238728,0.004689025,0.0003143762,0.004301597,0.05447677],"study_design_scores_gemma":[0.9159372,0.07291633,0.00559142,0.0000678432,0.001069495,0.0002486908,0.00008935596,0.0009344046,0.0004901119,0.0004343624,0.00217901,0.00004177786],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857807,0.008612377,0.0003007294,0.001210713,0.0003717904,0.0006436912,0.001317508,0.0001140837,0.0016484],"genre_scores_gemma":[0.9866034,0.005051668,0.001007307,0.001216473,0.0002517924,0.0006846588,0.002442721,0.00003119579,0.002710711],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003601403,"threshold_uncertainty_score":0.01204789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06301962313348018,"score_gpt":0.3484888677724673,"score_spread":0.2854692446389872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}